Systemic treatment in the management of head and neck cutaneous malignancies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

For many advanced cutaneous malignancies, combined modality approaches with surgery, radiation, and systemic treatment with chemotherapy and/or biotherapy can maximize outcome for skin cancers of head and neck regions. Use of systemic therapies when given together or separately from radiation therapy, as the case may be, can often lead to better outcomes, with less overall morbidity and a higher likelihood of complete extirpative surgery. Good examples of this concept would be the use of concurrent chemoradiation for locally advanced squamous cell carcinoma of the skin, in which very large invasive tumors can be rendered dramatically smaller, if not completely gone. A novel oral biological drug that targets the Hedgehog signaling pathway, vismodegib, can shrink initially locally advanced unresectable basal cell carcinomas to a resectable, if not completely regressed, and hence curable state with the need for less aggressive and potentially disfiguring surgery. Adjuvant systemic therapies given after definitive surgery may also improve survival by reducing the likelihood of metastatic relapse in patients with aggressive melanoma or Merkel cell carcinoma. This review will provide further detail with regard to the use of some of the available systemic treatments for the common cutaneous malignancies of the head and neck, including squamous cell carcinoma, basal cell carcinoma, malignant melanoma, and Merkel cell carcinoma, to provide a better understanding of the multimodality approaches in these malignancies.

Original languageEnglish (US)
Pages (from-to)63-68
Number of pages6
JournalOperative Techniques in Otolaryngology - Head and Neck Surgery
Volume24
Issue number1
DOIs
StatePublished - Mar 1 2013

Fingerprint

Neck
Head
Merkel Cell Carcinoma
Skin
Basal Cell Carcinoma
HhAntag691
Melanoma
Neoplasms
Biological Therapy
Skin Neoplasms
Therapeutics
Head and Neck Neoplasms
Squamous Cell Carcinoma
Radiotherapy
Radiation
Morbidity
Recurrence
Drug Therapy
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Otorhinolaryngology

Cite this

@article{ed46a5ee1a23474f880b388740523d30,
title = "Systemic treatment in the management of head and neck cutaneous malignancies",
abstract = "For many advanced cutaneous malignancies, combined modality approaches with surgery, radiation, and systemic treatment with chemotherapy and/or biotherapy can maximize outcome for skin cancers of head and neck regions. Use of systemic therapies when given together or separately from radiation therapy, as the case may be, can often lead to better outcomes, with less overall morbidity and a higher likelihood of complete extirpative surgery. Good examples of this concept would be the use of concurrent chemoradiation for locally advanced squamous cell carcinoma of the skin, in which very large invasive tumors can be rendered dramatically smaller, if not completely gone. A novel oral biological drug that targets the Hedgehog signaling pathway, vismodegib, can shrink initially locally advanced unresectable basal cell carcinomas to a resectable, if not completely regressed, and hence curable state with the need for less aggressive and potentially disfiguring surgery. Adjuvant systemic therapies given after definitive surgery may also improve survival by reducing the likelihood of metastatic relapse in patients with aggressive melanoma or Merkel cell carcinoma. This review will provide further detail with regard to the use of some of the available systemic treatments for the common cutaneous malignancies of the head and neck, including squamous cell carcinoma, basal cell carcinoma, malignant melanoma, and Merkel cell carcinoma, to provide a better understanding of the multimodality approaches in these malignancies.",
author = "Matthew Evans and Joseph Drabick",
year = "2013",
month = "3",
day = "1",
doi = "10.1016/j.otot.2013.01.002",
language = "English (US)",
volume = "24",
pages = "63--68",
journal = "Operative Techniques in Otolaryngology - Head and Neck Surgery",
issn = "1043-1810",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Systemic treatment in the management of head and neck cutaneous malignancies

AU - Evans, Matthew

AU - Drabick, Joseph

PY - 2013/3/1

Y1 - 2013/3/1

N2 - For many advanced cutaneous malignancies, combined modality approaches with surgery, radiation, and systemic treatment with chemotherapy and/or biotherapy can maximize outcome for skin cancers of head and neck regions. Use of systemic therapies when given together or separately from radiation therapy, as the case may be, can often lead to better outcomes, with less overall morbidity and a higher likelihood of complete extirpative surgery. Good examples of this concept would be the use of concurrent chemoradiation for locally advanced squamous cell carcinoma of the skin, in which very large invasive tumors can be rendered dramatically smaller, if not completely gone. A novel oral biological drug that targets the Hedgehog signaling pathway, vismodegib, can shrink initially locally advanced unresectable basal cell carcinomas to a resectable, if not completely regressed, and hence curable state with the need for less aggressive and potentially disfiguring surgery. Adjuvant systemic therapies given after definitive surgery may also improve survival by reducing the likelihood of metastatic relapse in patients with aggressive melanoma or Merkel cell carcinoma. This review will provide further detail with regard to the use of some of the available systemic treatments for the common cutaneous malignancies of the head and neck, including squamous cell carcinoma, basal cell carcinoma, malignant melanoma, and Merkel cell carcinoma, to provide a better understanding of the multimodality approaches in these malignancies.

AB - For many advanced cutaneous malignancies, combined modality approaches with surgery, radiation, and systemic treatment with chemotherapy and/or biotherapy can maximize outcome for skin cancers of head and neck regions. Use of systemic therapies when given together or separately from radiation therapy, as the case may be, can often lead to better outcomes, with less overall morbidity and a higher likelihood of complete extirpative surgery. Good examples of this concept would be the use of concurrent chemoradiation for locally advanced squamous cell carcinoma of the skin, in which very large invasive tumors can be rendered dramatically smaller, if not completely gone. A novel oral biological drug that targets the Hedgehog signaling pathway, vismodegib, can shrink initially locally advanced unresectable basal cell carcinomas to a resectable, if not completely regressed, and hence curable state with the need for less aggressive and potentially disfiguring surgery. Adjuvant systemic therapies given after definitive surgery may also improve survival by reducing the likelihood of metastatic relapse in patients with aggressive melanoma or Merkel cell carcinoma. This review will provide further detail with regard to the use of some of the available systemic treatments for the common cutaneous malignancies of the head and neck, including squamous cell carcinoma, basal cell carcinoma, malignant melanoma, and Merkel cell carcinoma, to provide a better understanding of the multimodality approaches in these malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84875890073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875890073&partnerID=8YFLogxK

U2 - 10.1016/j.otot.2013.01.002

DO - 10.1016/j.otot.2013.01.002

M3 - Article

VL - 24

SP - 63

EP - 68

JO - Operative Techniques in Otolaryngology - Head and Neck Surgery

JF - Operative Techniques in Otolaryngology - Head and Neck Surgery

SN - 1043-1810

IS - 1

ER -